Mar 7, 2023

Medtronic innovation elevates patient care in sacral neuromodulation therapy

adding value

Medtronic is pleased to debut a first-of-its-kind smartphone app at the winter meeting of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) that will advance the ability of physicians to navigate the sacral neuromodulation (SNM) patient journey and provide personalized education to patients about their therapy pre- and post-implant. The MyJourneyTM app synthesizes data entered by the patient while tracking their overactive bladder symptoms to provide the physician with easily accessible, streamlined reports to support conversations about care. The app also provides the patient with personalized support and education based on their therapy stage throughout the SNM journey.

“Innovating an enhanced patient experience with digital health data is a big step forward in SNM therapy,” said Jannah H. Thompson, M.D., FPMRS, immediate past president of the Society of Women in Urology (SWIU), and urologist at Urologic Consultants in Grand Rapids, Michigan. “This app will improve my ability to have meaningful conversations with my patients so I can give them truly personalized care and ensure they have the continued support and resources they need after leaving my office.”

A diary showing at least 50 percent or greater relief in symptoms during the evaluation period is a required step for U.S. insurance reimbursement in the SNM implant process. Digitized symptom tracking improves the patient experience compared to the traditional paper diary, which can be difficult to remember and use discreetly in public, and can be lost. The MyJourney app provides an intuitive way for patients to track their symptoms, keeps patients engaged through reminders and notifications, and ensures their data is securely stored. Patients also receive personalized education content on their app, based on their therapy stage, so they are supported outside of scheduled visits with their physician.

“Putting the patient at the center of our decisions is core to the Medtronic InterStimTM brand,” said Mira Sahney, president of the Pelvic Health operating unit at Medtronic, a part of the Neuroscience portfolio. “Our unparalleled experience in therapy development for bladder and bowel dysfunction has taught us that reaching more patients means innovation must go beyond devices to the entire patient and physician experience. We’re excited about how patient-centric innovation and data-driven insights will shape the future of care in our space.”

The MyJourney app will be available for download and use in the U.S. beginning in April 2023.

For more information, visit



Katie Genereux                                                                        Ryan Weispfenning
Public Relations                                                                        Investor Relations
+1-763-514-0162                                                                    +1-763-505-4626